178990-29-9Relevant academic research and scientific papers
4-aminoquinoline compound, and preparation method and application thereof
-
Paragraph 0032; 0043-0046, (2019/11/12)
The invention discloses a 4-aminoquinoline compound, and a preparation method and application thereof. The second site of the 4-aminoquinoline compound is replaced by cyclic R-base, the 4-aminoquinoline compound is obtained by 4-step reaction of anthranil
AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
-
Page/Page column 136; 138, (2009/10/06)
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
Oxadiazoles as bioisosteric transformations of carboxylic functionalities. II
Andersen,Lundt,Jorgensen,Braestrup
, p. 417 - 425 (2007/10/03)
In order to improve the in vivo efficacy of a series of known benzodiazepine receptor (BZR) ligands, 1-(2-phenyl-4-quinolinyl)-4-piperidinecarboxamides, a series of analogs has been prepared in which the amide group of these ligands has been replaced by a 1,2,4-oxadiazole moiety or converted to other carboxylic isosters such as esters or nitriles. An increase in the in vivo efficacy was observed for some of the compounds prepared in this investigation compared to the parent carboxamide derivatives.
